# Effects of Tolperisone on Measures of Drowsiness and Cognitive Function

> **NCT04407377** · PHASE1 · COMPLETED · sponsor: **Neurana Pharmaceuticals, Inc.** · enrollment: 39 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Tolperisone Hydrochloride
- **DRUG:** Cyclobenzaprine Hydrochloride 10 MG
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04407377
- **Lead sponsor:** Neurana Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-20
- **Primary completion:** 2020-10-16
- **Final completion:** 2021-03-31
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2022-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04407377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04407377, "Effects of Tolperisone on Measures of Drowsiness and Cognitive Function". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04407377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*